Anthem Biosciences: Anthem Biosciences shares get listed at 27% premium!Anthem Biosciences: Anthem Biosciences shares get listed at 27% premium!

Anthem Biosciences Ltd. saw a solid debut on Dalal Street on July 21, with its shares listing at ₹723.10 on the BSE and ₹723.05 on the NSE, marking a 26.85% premium over the IPO issue price of ₹570 on both exchanges.

Also Read: Q1 Results: Oil stock falls 7% after reporting ₹270 Cr loss against net profit of ₹73 Cr an yr ago

The ₹3,395 crore IPO of Anthem Biosciences, an entirely offer for sale, was open from July 14 to 16. It saw strong demand with 67.42 times overall subscription, including 192.80 times by QIBs, and ₹1,016 crore raised from anchor investors.

Anthem Biosciences Ltd, founded in 2006, is a technology-driven CRDMO offering end-to-end drug discovery, development, and manufacturing services. It caters globally to biotech and pharmaceutical firms, specializing in fermentation-based APIs like enzymes, probiotics, peptides, and biosimilars.

Also Read: Stock jumps 12% after Mukul Agrawal increases 2.5% stake in the company

The objective of Anthem Biosciences’ IPO was to facilitate an offer for sale by existing shareholders, allowing them to liquidate part of their holdings. The company did not receive any proceeds, as no fresh issue of shares was involved.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.